Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma
- PMID: 629636
Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma
Abstract
Knowledge of the prognostic factors that characterize a disease can assist in planning and analyzing clinical trials. The present study was conducted to determine the characteristics related to response and survival in patients with stage III and IV non-Hodgkin's lymphoma who were treated with combinations of cyclophosphamide, vincristine sulfate, and prednisone. Considering each characteristic individually and using stepwise regression analysis, tumor bulkiness, prior therapy, sex, and pretreatment lymphocyte count were selected as the four most important prognostic variables. Tumor architecture (diffuse or nodular pattern) and cell type, hemoglobin level, and symptoms although not important in predicting response were found to be important in predicting survival. The hemoglobin level had only marginal importance in predicting response. Factors found not be important were age, stage, symptoms, cell type, nodularity, marrow involvement, prior extensive radiotherapy, and bone involvement. A logistic regression equation has been derived that can be used to predict response rate.
Similar articles
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
-
Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M).Jpn J Clin Oncol. 1988 Jun;18(2):113-24. Jpn J Clin Oncol. 1988. PMID: 3379782 Clinical Trial.
-
[Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].Ai Zheng. 2006 Aug;25(8):1013-8. Ai Zheng. 2006. PMID: 16965685 Chinese.
-
[Cyclophosphamide-vincristine-prednisone combination in the treatment of lympho- and reticulosarcomas in adults (60 cases)].Nouv Presse Med. 1976 Nov 13;5(38):2525-30. Nouv Presse Med. 1976. PMID: 790316 French.
-
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.J Clin Oncol. 2003 Jun 1;21(11):2115-22. doi: 10.1200/JCO.2003.07.111. J Clin Oncol. 2003. PMID: 12775737 Review.
Cited by
-
Prognostic factors in non-Hodgkin's lymphoma: the importance of symptomatic stage as an adjunct to the Kiel histopathological classification.Br J Cancer. 1983 Jan;47(1):91-102. doi: 10.1038/bjc.1983.11. Br J Cancer. 1983. PMID: 6821635 Free PMC article.
-
Prognostic factors in the non-Hodgkin's lymphomas--a time for consensus?Br J Cancer. 1991 Jun;63(6):837-40. doi: 10.1038/bjc.1991.186. Br J Cancer. 1991. PMID: 2069841 Free PMC article. Review. No abstract available.
-
A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party.Br J Cancer. 1991 Jun;63(6):945-52. doi: 10.1038/bjc.1991.207. Br J Cancer. 1991. PMID: 2069849 Free PMC article. Clinical Trial.
-
Prognostic significance of biochemical markers in African Burkitt's lymphoma.Clin Transl Oncol. 2011 Oct;13(10):731-6. doi: 10.1007/s12094-011-0724-8. Clin Transl Oncol. 2011. PMID: 21975335
-
Symptoms in cancer of the pancreas.J R Coll Physicians Lond. 1979 Apr;13(2):90-2. J R Coll Physicians Lond. 1979. PMID: 439048 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources